Literature DB >> 16273997

Alpha-Synuclein aggregation in pathological aging and Alzheimer's disease: the impact of beta-amyloid plaque level.

Sara M Lippa1, Carol F Lippa, Hiroshi Mori.   

Abstract

In central nervous system diseases, abnormal aggregation of one protein is often associated with aggregation of other proteins. To begin to assess whether beta-amyloid (Abeta) is associated with alpha-synuclein (AS) aggregation [secondary Lewy body (LB) formation], we used immunohistochemical techniques to compare the amygdala of 11 subjects with pathological aging and 18 with Alzheimer's disease. Overall, Abeta-40 plaque level was greater in cases with secondary AS aggregates. Abeta-42 plaque level was not associated with AS aggregation. Abeta-40 plaque levels cannot be ruled out as a factor involved in secondary LB formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273997     DOI: 10.1177/153331750502000506

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  13 in total

1.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

Review 2.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

3.  Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization.

Authors:  Jason Candreva; Edward Chau; Margaret E Rice; Jin Ryoun Kim
Journal:  Biochemistry       Date:  2019-12-30       Impact factor: 3.162

4.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

5.  Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity.

Authors:  Peter T Nelson; Gregory A Jicha; Frederick A Schmitt; Huaichen Liu; Daron G Davis; Marta S Mendiondo; Erin L Abner; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2007-12       Impact factor: 3.685

6.  Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Authors:  Tetyana Duka; Valeriy Duka; Jeffrey N Joyce; Anita Sidhu
Journal:  FASEB J       Date:  2009-04-15       Impact factor: 5.191

7.  Cerebral amyloid angiopathy in Lewy body disease.

Authors:  K A Jellinger; J Attems
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

8.  Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?

Authors:  B Mollenhauer; M Bibl; H Esselmann; P Steinacker; C Trenkwalder; J Wiltfang; M Otto
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

9.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

10.  Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases.

Authors:  Nicole M Desforges; Michaeline L Hebron; Norah K Algarzae; Irina Lonskaya; Charbel E-H Moussa
Journal:  Int J Alzheimers Dis       Date:  2012-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.